AAV-sBTLA facilitates HSP70 vaccine-triggered prophylactic antitumor immunity against a murine melanoma pulmonary metastasis model in vivo

Cancer Letters

Volumn 354, Issue 2, 2014, Pages 398-406

  Han, Lingfei ^a   Wang, Wei ^b   Lu, Jiahong ^c   Kong, Fanfei ^a   Ma, Ge ^c   Zhu, Yiping ^a   Zhao, Dong ^a   Zhu, Jianlong ^a   Shuai, Wen ^a   Zhou, Qian ^a   Chen, Ping ^a   Ye, Lei ^a   Tao, Jie ^a   Ahmad, Sarfraz ^d   Li, Fang ^a   Sun, Jing ^a  

^a TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d FLORIDA HOSPITAL CANCER INSTITUTE   (United States)

Author keywords

AAV; BTLA; HSP70 vaccine; Immunotherapy; Metastatic melanoma

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70 VACCINE; INTERLEUKIN 10; INTERLEUKIN 2; LYMPHOCYTE RECEPTOR; PARVOVIRUS VECTOR; SOLUBLE B AND T LYMPHOCYTE ATTENUATOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; BTLA PROTEIN, MOUSE; HEAT SHOCK PROTEIN 70; IMMUNOGLOBULIN RECEPTOR;

ADENO ASSOCIATED VIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER PREVENTION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION REGULATION; IFN GAMMA GENE; IL 2 GENE; IL10 GENE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LYMPHOCYTE ACTIVATION; MELANOMA CELL LINE; MELANOMA METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; SBTLA GENE; TGF BETA1 GENE; TH1 CELL; TOXICITY TESTING; TUMOR MICROENVIRONMENT; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; ANIMAL; CHO CELL LINE; CRICETULUS; DEPENDOPARVOVIRUS; GENETIC TRANSFECTION; GENETICS; IMMUNOLOGY; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; PATHOLOGY; SECONDARY;

ANIMALS; CANCER VACCINES; CHO CELLS; CRICETULUS; DEPENDOVIRUS; FEMALE; HSP70 HEAT-SHOCK PROTEINS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; RECEPTORS, IMMUNOLOGIC; TRANSFECTION;

EID: 84907982001     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.08.006     Document Type: Article

References (37)

1. Das Thakur M., Stuart D.D. The evolution of melanoma resistance reveals therapeutic opportunities. Cancer Res 2013, 73:6106-6110.
2. Radvanyi L.G., Bernatchez C., Zhang M., Fox P.S., Miller P., Chacon J., et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res 2012, 18:6758-6770.
3. Kwong M.L., Neyns B., Yang J.C. Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy. Clin. Cancer Res 2013, 19:5292-5299.
4. Kaufman H.L., Kirkwood J.M., Hodi F.S., Agarwala S., Amatruda T., Bines S.D., et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat. Rev. Clin. Oncol 2013, 10:588-598.
5. Dannull J., Haley N.R., Archer G., Nair S., Boczkowski D., Harper M., et al. Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. J. Clin. Invest 2013, 123:3135-3145.
6. Simpson T.R., Li F., Montalvo-Ortiz W., Sepulveda M.A., Bergerhoff K., Arce F., et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med 2013, 210:1695-1710.
7. Li Y., Liu S., Hernandez J., Vence L., Hwu P., Radvanyi L. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J. Immunol 2010, 184:452-465.
8. Watanabe N., Gavrieli M., Sedy J.R., Yang J., Fallarino F., Loftin S.K., et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat. Immunol 2003, 4:670-679.
9. Gonzalez L.C., Loyet K.M., Calemine-Fenaux J., Chauhan V., Wranik B., Ouyang W., et al. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc. Natl Acad. Sci. U.S.A. 2005, 102:1116-1121.
10. Sedy J.R., Gavrieli M., Potter K.G., Hurchla M.A., Lindsley R.C., Hildner K., et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat. Immunol 2005, 6:90-98.
11. Murphy K.M., Nelson C.A., Sedy J.R. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat. Rev. Immunol 2006, 6:671-681.
12. Gertner-Dardenne J., Fauriat C., Orlanducci F., Thibult M.L., Pastor S., Fitzgibbon J., et al. The co-receptor BTLA negatively regulates human Vgamma9Vdelta2 T-cell proliferation: a potential way of immune escape for lymphoma cells. Blood 2013, 122:922-931.
13. Fourcade J., Sun Z., Pagliano O., Guillaume P., Luescher I.F., Sander C., et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 2012, 72:887-896.
14. Geng H., Zhang G.M., Xiao H., Yuan Y., Li D., Zhang H., et al. HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma. Int. J. Cancer 2006, 118:2657-2664.
15. Han L., Wang W., Fang Y., Feng Z., Liao S., Li W., et al. Soluble B and T lymphocyte attenuator possesses antitumor effects and facilitates heat shock protein 70 vaccine-triggered antitumor immunity against a murine TC-1 cervical cancer model in vivo. J. Immunol 2009, 183:7842-7850.
16. Xiao H., Huang B., Yuan Y., Li D., Han L.F., Liu Y., et al. Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo. Clin. Cancer Res 2007, 13:1823-1830.
17. Lasaro M.O., Ertl H.C. Potentiating vaccine immunogenicity by manipulating the HVEM/BTLA pathway and other co-stimulatory and co-inhibitory signals of the immune system. Hum. Vaccin 2009, 5:6-14.
18. Derre L., Rivals J.P., Jandus C., Pastor S., Rimoldi D., Romero P., et al. BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination. J. Clin. Invest 2010, 120:157-167.
19. Tamayose K., Hirai Y., Shimada T. A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography. Hum. Gene Ther 1996, 7:507-513.
20. Rohr U.P., Wulf M.A., Stahn S., Steidl U., Haas R., Kronenwett R. Fast and reliable titration of recombinant adeno-associated virus type-2 using quantitative real-time PCR. J. Virol. Methods 2002, 106:81-88.
21. He Y.F., Zhang G.M., Wang X.H., Zhang H., Yuan Y., Li D., et al. Blocking programmed death-1 ligand-PD-1 interactions by local gene therapy results in enhancement of antitumor effect of secondary lymphoid tissue chemokine. J. Immunol 2004, 173:4919-4928.
22. Lim S.A., Kim T.J., Lee J.E., Sonn C.H., Kim K., Kim J., et al. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. Cancer Res 2013, 73:2598-2607.
23. Liang S.C., Moskalenko M., Van Roey M., Jooss K. Depletion of regulatory T cells by targeting folate receptor 4 enhances the potency of a GM-CSF-secreting tumor cell immunotherapy. Clin. Immunol 2013, 148:287-298.
24. Kuhn S., Hyde E.J., Yang J., Rich F.J., Harper J.L., Kirman J.R., et al. Increased numbers of monocyte-derived dendritic cells during successful tumor immunotherapy with immune-activating agents. J. Immunol 2013, 191:1984-1992.
25. Lesokhin A.M., Hohl T.M., Kitano S., Cortez C., Hirschhorn-Cymerman D., Avogadri F., et al. Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. Cancer Res 2012, 72:876-886.
26. Facciabene A., Motz G.T., Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012, 72:2162-2171.
27. Pasero C., Olive D. Interfering with coinhibitory molecules: BTLA/HVEM as new targets to enhance anti-tumor immunity. Immunol. Lett 2013, 151:71-75.
28. Crawford A., Wherry E.J. Editorial: therapeutic potential of targeting BTLA. J. Leukoc. Biol 2009, 86:5-8.
29. Mingozzi F., Chen Y., Edmonson S.C., Zhou S., Thurlings R.M., Tak P.P., et al. Prevalence and pharmacological modulation of humoral immunity to AAV vectors in gene transfer to synovial tissue. Gene Ther 2013, 20:417-424.
30. You C.X., Liu Y., Shi M., Cao M., Luo R.C., Hermonat P.L. Comparison of AAV/IL-7 autocrine (T cell) versus paracrine (DC) gene delivery for enhancing CTL stimulation and function. Cancer Immunol. Immunother 2010, 59:779-787.
31. Mingozzi F., High K.A. Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013, 122:23-36.
32. Mingozzi F., High K.A. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet 2011, 12:341-355.
33. Mingozzi F., High K.A. Immune responses to AAV in clinical trials. Curr. Gene Ther 2011, 11:321-330.
34. Pacak C.A., Byrne B.J. AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities. Mol. Ther 2011, 19:1582-1590.
35. Kurotaki T., Tamura Y., Ueda G., Oura J., Kutomi G., Hirohashi Y., et al. Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. J. Immunol 2007, 179:1803-1813.
36. Haymaker C., Wu R., Bernatchez C., Radvanyi L. PD-1 and BTLA and CD8(+) T-cell "exhaustion" in cancer: "exercising" an alternative viewpoint. Oncoimmunology 2012, 1:735-738.
37. Lasaro M.O., Tatsis N., Hensley S.E., Whitbeck J.C., Lin S.W., Rux J.J., et al. Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses. Nat. Med 2008, 14:205-212.